Company & Sponsor Intelligence
Bayer
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials7
Recruiting3
Completed3
Countries3
Therapeutic footprint
alzheimersmultiple_sclerosisout_of_scopeparkinsons
Indexed studies
NCT07298044A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
out_of_scope · AustriaPHASE4
out_of_scope · AustriaPHASE4
NCT00761436Pilot Study of Safety and Efficacy of Spheramine
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
out_of_scope · United StatesPHASE3
out_of_scope · United StatesPHASE3
NCT01009359Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
alzheimers · FinlandPHASE1
alzheimers · FinlandPHASE1
NCT00791778Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
out_of_scope · United StatesPHASE2
out_of_scope · United StatesPHASE2
NCT05196035A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
out_of_scope · United StatesPHASE3
out_of_scope · United StatesPHASE3
NCT03408093Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
multiple_sclerosis · COMPLETED
multiple_sclerosis · COMPLETED
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →